We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+2.2%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$43.6B
AUM Growth
+$2.01B
(+4.8%)
Cap. Flow
+$1.75B
Cap. Flow
% of AUM
4%
Top 10 Holdings %
Top 10 Hldgs %
18.28%
Holding
1,493
New
278
Increased
387
Reduced
400
Closed
399
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$674M |
| 2 |
IBM
IBM
|
+$408M |
| 3 |
Toronto Dominion Bank
TD
|
+$392M |
| 4 |
Biogen
BIIB
|
+$340M |
| 5 |
Boeing
BA
|
+$319M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Philip Morris
PM
|
+$366M |
| 2 |
CVS Health
CVS
|
+$350M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
+$333M |
| 4 |
TSMC
TSM
|
+$323M |
| 5 |
Merck
MRK
|
+$283M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.47% |
| 2 | Healthcare | 17.17% |
| 3 | Financials | 16.49% |
| 4 | Consumer Discretionary | 12.16% |
| 5 | Industrials | 11.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
TSMC
TSM
$2.17T
| $376M | 0.86% |
8,589,725
-7,406,086
| -46% | -$323M |
|
27
Vertex Pharmaceuticals
VRTX
$124B
| $346M | 0.79% |
2,125,216
+921,995
| +77% | +$151M |
|
28
Rio Tinto
RIO
$165B
| $343M | 0.79% |
6,657,336
+2,165,883
| +48% | +$118M |
|
29
McDonald's
MCD
$195B
| $340M | 0.78% |
2,172,237
+1,165,500
| +116% | +$192M |
|
|
RHT
30
DELISTED
Red Hat Inc
RHT
| $334M | 0.77% |
2,235,150
+90,550
| +4% | +$12.6M |
|
31
Petrobras
PBR
$117B
| $320M | 0.73% |
22,618,523
+12,078,069
| +115% | +$159M |
|
|
32
Biogen
BIIB
$30.3B
| $313M | 0.72% |
1,143,854
+1,094,854
| +2,234% | +$340M |
|
33
Las Vegas Sands
LVS
$29.6B
| $301M | 0.69% |
4,190,578
+1,921,180
| +85% | +$141M |
|
34
SiriusXM
SIRI
$10B
| $293M | 0.67% |
4,700,959
+318,484
| +7% | +$19.1M |
|
35
Capital One
COF
$133B
| $290M | 0.67% |
3,026,754
-940,569
| -24% | -$93.6M |
|
|
MRSH
36
Marsh
MRSH
$91.4B
| $272M | 0.62% |
3,291,819
+739,653
| +29% | +$61.3M |
|
37
Constellation Brands
STZ
$23.2B
| $269M | 0.62% |
1,179,284
-4,653
| -0.4% | -$1.02M |
|
38
HCA Healthcare
HCA
$88.8B
| $268M | 0.62% |
2,766,713
-214,242
| -7% | -$20.8M |
|
39
Visa
V
$681B
| $267M | 0.61% |
2,234,041
-758,597
| -25% | -$91.9M |
|
40
Cigna
CI
$73.9B
| $262M | 0.6% |
1,560,143
+939,830
| +152% | +$183M |
|
|
41
Philip Morris
PM
$295B
| $261M | 0.6% |
2,622,091
-3,514,467
| -57% | -$366M |
|
42
Gilead Sciences
GILD
$165B
| $239M | 0.55% |
3,175,747
+105,420
| +3% | +$8.38M |
|
43
Cognizant
CTSH
$25.7B
| $237M | 0.54% |
2,938,137
-1,484,456
| -34% | -$117M |
|
44
Best Buy
BBY
$17.2B
| $228M | 0.52% |
3,252,754
+1,131,260
| +53% | +$81.3M |
|
45
Align Technology
ALGN
$12.1B
| $227M | 0.52% |
904,234
+184,823
| +26% | +$47.5M |
|
46
AB InBev
BUD
$166B
| $227M | 0.52% |
+2,063,707
| New | +$229M |
|
47
Banco Bradesco
BBD
$37B
| $222M | 0.51% |
32,889,463
+14,960,291
| +83% | +$99.8M |
|
48
US Bancorp
USB
$99.6B
| $220M | 0.5% |
4,348,274
+2,818,751
| +184% | +$154M |
|
|
ESRX
49
DELISTED
Express Scripts Holding Company
ESRX
| $214M | 0.49% |
3,094,266
-356,578
| -10% | -$27.2M |
|
50
Idexx Laboratories
IDXX
$46.9B
| $206M | 0.47% |
1,074,989
-179,424
| -14% | -$33.1M |
|
Similar funds
VGA
Arrowstreet Capital's Q1 2018 Portfolio in Review
As of Q1 2018, Arrowstreet Capital held 1,493 positions worth $43.6B, up 4.8% from $41.6B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Arrowstreet Capital deployed $1.75B of net new capital in Q1 2018, opening 278 new positions and adding to 387 existing holdings. Its largest new stake was AB InBev: 2,063,707 shares worth $227M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Philip Morris, an estimated $366M trimmed.
- Arrowstreet Capital's largest Q1 2018 buy was AB InBev: 2,063,707 shares worth $227M.
- Arrowstreet Capital added most to AbbVie in Q1 2018, an estimated $674M increase.
- Arrowstreet Capital's biggest Q1 2018 reduction was Philip Morris, cutting an estimated $366M.
- Arrowstreet Capital fully exited iShares MSCI South Korea ETF in Q1 2018, selling an estimated $271M.
- Arrowstreet Capital's ten largest holdings make up 18% of its $43.6B portfolio in Q1 2018.
- Arrowstreet Capital opened 278 new positions and closed 399 in Q1 2018.
- Arrowstreet Capital's portfolio value rose 4.8% quarter-over-quarter to $43.6B.
Based on Arrowstreet Capital's 13F filing for Q1 2018, filed 14 May 2018.